Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3630MR)

This product GTTS-WQ3630MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3630MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12607MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ13076MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ12623MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ9228MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ11512MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ2609MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ1323MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ2109MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW